TREATMENT EFFICACY AND SOME ADVERSE EFFECTS OF CHEMOTHERAPY REGIMENS CONTAINING TS-1 IN INOPERABL GASTRIC CANCER

Tóm tắt

Objectives: To evaluate the effectiveness and associated adverse effects of chemotherapy regiment containing TS-1 in patients with inoperable gastric cancer.

Subjects and methods: Prospective study, cross-sectional description, longitudinal follow-up in 68 patients with inoperable gastric cancer treated with systemic chemotherapy using the chemical regimens TS-1 alone, TS-1 combined with Oxaliplatin and TS-1 combined with Cisplatin at Central Hospital 108 from 10-2019 to 6-2023. Treatment response was assessed using the RECIST, Adverse effects were evaluated using the CTCAE v.3.0. while survival time was estimated via the Kaplan-Meier method.

Results: The average age of patients was 63.5 ± 10.68. Common metastatic organs included peritoneum (47.1%), liver (36.8%) and lymph nodes (29.7%). Most patients (89.7%) had metastases in multiple organs, with 47.1% affecting two or more sites. The partial response rates and disease control rates were 38.2% and 82.3%, respectively, with no patients achieving complete response. The median progression-free survival was 6.5 months. The median overall survival was 10.9 months. The most common adverse event was neutropenia in 55.9% (22.1% grade 3 or higher). Hand-foot syndrome and neuropathy were uncommon and mostly mild.

Conclusions: The treatment 68 patients of inoperable gastric cancer with chemotherapy containing TS-1 had disease control rates and progression-free survival times comparable to those in published phase 3 trials, and controlled adverse events.